medigraphic.com

2020, Number 2

<< Back Next >>

Rev Fac Med UNAM 2020; 63 (2)

Polyenic Antifungals. Action Mechanisms and their Applications

Rivera-Toledo E, Jiménez-Delgadillo AU, Manzano-Gayosso P

Language: Spanish
References: 36
Page: 7-17
PDF size: 545.00 Kb.


ABSTRACT

The first compounds with specific antifungal activity were identified in the middle of the last century as a product of the secondary metabolism of bacteria of the order Actinomycetales, and their clinical use significantly diminished the morbidity and mortality associated with severe fungal infections. Many of such biosynthetic compounds are characterized by a chemical polygenic structure, with a variable number of carbon-carbon double bonds. Currently, besides polygenic antimycotics, there are other antifungal agents, such as the azole compounds, that have less toxicity in patients; however, cases of therapeutic failure with such compounds have been documented, therefore, the use of polygenics is still the best alternative in such cases. This review presents data about the properties and applications of antifungal-polygenic compounds using amphotericin B as a model.


REFERENCES

  1. Galagan JE, Henn MR, Ma LJ, Cuomo CA, Birren B. Genomics of the fungal kingdom: Insights into eukaryotic biology. Genome Res. 2005;15(12):1620-31.

  2. Editorial Nat Microbiol. Stop neglecting fungi. Nat Microbiol. 2017;2(17120):1.

  3. Bongomin F, Gago S, Oladele R, Denning D. Global and multi-national prevalence of fungal diseases —estimate precision. J Fungi (Basel). 2017;3(4):57.

  4. Galanis E, MacDougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis. 2010;16(2):251-7.

  5. Miguel P, Allevato AJ, Negroni PR, Galimberti PR. Antifúngicos ayer, hoy y mañana. Act Terap Dermatol. 2007; 30:8-19.

  6. Waksman SA, Lechevalier HA, Schaffner CP. Candicidin and other polyenic antifungal antibiotics. Bull World Health Organ. 1965;33(2):219-26.

  7. Brautaset T, Sletta H, Degnes KF, Sekurova ON, Bakke I, Volokhan O, et al. New nystatin-related antifungal polyene macrolides with altered polyol region generated via biosynthetic engineering of Streptomyces noursei. Appl Environ Microbiol. 2011;77(18):6636-43.

  8. Blum G, Hörtnagl C, Jukic E, Erbeznik T, Pümpel T, Dietrich H, et al. New Insight into Amphotericin B Resistance in Aspergillus terreus. Antimicr Agents Chemother. 2013; 57(4):1583-8.

  9. Mellado F, Rojas T, Cumsille C. Queratitis fúngica: revisión actual sobre diagnóstico y tratamiento. Arq Bras Oftalmol. 2013;76(1):52-6.

  10. COFEPRIS. Aditivos Alimentarios Anexo I: Aditivos con diversas clases funcionales y con una IDA establecida. 2015;1-9.

  11. Opekarova M, Tanner W. Membrane transport inhibition as mode of action of polyene antimycotics: recent data supported by old ones. Food Technol Biotechnol. 2014;52(1):8- 12.

  12. Perea JRA, Barberán J. Anfotericina B forma liposómica: Un perfil farmacocinético exclusivo. Una historia inacabada. Rev Esp Quimioter. 2012;25(1):17-24.

  13. Cohen BE. Amphotericin B membrane action: Role for two types of ion channels in eliciting cell survival and lethal effects. J Membr Biol. 2010;238(1-3):1-20.

  14. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci USA. 2012;109(7): 2234-9.

  15. Grudzinski W, Sagan J, Welc R, Luchowski R, Gruszecki WI. Molecular organization, localization and orientation of antifungal antibiotic amphotericin B in a single lipid bilayer. Sci Rep. 2016;32780-90.

  16. Delattin N, Cammue BP, Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms. Future Med Chem. 2014;6(1):77-90.

  17. Darisipudi MN, Allam R, Rupanagudi KV. Polyene macrolide antifungal drugs trigger interleukin-1 b secretion by activating the NLRP3 inflammasome. PLOS one. 2011;6(5):1-6.

  18. Sangalli-Leite F, Scorzoni L, Mesa-Arango AC, Casas C, Herrero E, Soares Mendes Gianinni MJ, et al. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect. 2011;13(5):457-67.

  19. Bes DF, Sberna N, Rosanova MT. Advantages and drawbacks of amphotericin formulations in children: Literature review. Arch Argent Pediatr. 2012;110(1):46-51.

  20. Walker L, Sood P, Lenardon MD, Milne G, Olson J, Jensen G, et al. The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles. Mbio. 2018;9(1):1-15.

  21. Deak E, Wilson SD, White E, Carr JH, Balajee SA. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLOS one. 2009;4(10):1-7.

  22. Bennett J, Dolin R, Blaser M. Principles and practice of infectious diseases. 8th ed. Elsevier, Philadelphia, USA; 2016.

  23. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman. Las bases farmacológicas de la terapéutica. 11ª ed. McGraw-Hill Interamericana Editores, México; 2007.

  24. Villegas-Flores M, Castellanos-González MA, Beltrán Díazde la Vega F. Análisis de queratitis micóticas en un hospital de tercer nivel. Rev Mex Oftalmol. 2012;86(4):231-9.

  25. Catalán M, Montejo C. Antifúngicos sistémicos. Farmacodinamia y farmacocinética. Rev Iberoam Micol. 2006; 23:39-49.

  26. Chang YL, Yu SJ, Heitman J, Wellington M, Chen YL. New facets of antifungal therapy. Virulence. 2017;8(2):222- 236.

  27. González E, Rada MA, Lumbreras C, Ramos JT, Aguado JM. Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity. Enferm Infecc Microbiol Clin. 2000;18(4):162-4.

  28. Gavalda J, Ruiz I. Recomendaciones para el tratamiento de la infección fúngica invasiva. Enferm Infecc Microbiol Clin. 2003;21(9):498-508.

  29. Quinteros AR, Fica CA, Abusada AN, Muñoz CL, Novoa MC, Gallardo AC. Uso de anfotericina B deoxicolato y sus reacciones adversas en un hospital universitario en Chile. Rev Chil Infectol. 2010;27(1):25-33.

  30. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999;43(2):267-71.

  31. Schlottfeldt FDS, Fernandes SM, Martins DM, Cordeiro P, Da Fonseca CD, Watanabe M et al. Prevention of amphotericin B nephrotoxicity through use of phytotherapeutic medication. Rev da Esc Enferm USP. 2015;49:73-8.

  32. Lumbreras C, Lizasoain M, Aguado JM. Antifúngicos de uso sistémico. Enferm Infecc Microbiol Clin. 2003;21(7):366-80.

  33. Botero MC, Puentes-Herrera M, Cortés JA. Lipid formulations of amphotericin B. Rev Chil Infectol. 2014;31(5): 518-27.

  34. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47(2):226-35.

  35. Nava-Ruiz A, Arbo-Sosa A. Infusión de desoxicolato de anfotericina B en 6 horas versus 24 horas en niños con leucemia aguda. Bol Med Hosp Infant Mex. 2006;63(2):84-93.

  36. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J Infect Dis. 1987;156(5):784-9.




2020     |     www.medigraphic.com